Pharmaceutical company Boehringer Ingelheim has announced that vets and farmers across the globe have reached the milestone of protecting more than 500 million pigs from the potentially devastating consequences of Mycoplasma hyopneumoniae by using Ingelvac MycoFLEX.
Launched by in the Americas, Asia and Europe in 2008, the vaccine is used for the treatment of weaned piglets to reduce lung lesions following infection with Mycoplasma hyopneumoniae. The vaccine is now market leader in many countries worldwide, including Argentina, Czech Republic, Germany, Italy, South Korea, Netherlands, Poland, Sweden, Taiwan and USA.
 “The number of doses of Ingelvac MycoFLEX that we’ve sold since the vaccine’s launch in 2008 shows that at least 500 million pigs have now been protected by its use,” said the company’s senior vice president of animal health, George Heidgerken. “Reaching this landmark in preventing diseases makes us proud.”